CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+19.75%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$250M
AUM Growth
+$250M
(+48%)
Cap. Flow
+$41.6M
Cap. Flow
% of AUM
16.63%
Top 10 Holdings %
Top 10 Hldgs %
60.98%
Holding
35
New
4
Increased
16
Reduced
4
Closed
2
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$10M |
| 2 |
Illumina
ILMN
|
$5.47M |
| 3 |
Gilead Sciences
GILD
|
$5.31M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
$4.92M |
| 5 |
Sangamo Therapeutics
SGMO
|
$4.84M |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$17.5M |
| 2 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$3.93M |
| 3 |
Pacific Biosciences
PACB
|
$1.42M |
| 4 |
Adverum Biotechnologies
ADVM
|
$1.13M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$988K |
Sector Composition
| 1 | Healthcare | 88.33% |
| 2 | Materials | 0.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $28.9M | 10.68% | 360,000 | – | – |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $20.3M | 7.51% | 255,000 | – | – |
|
|
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
| $19.1M | 7.06% | 480,000 | – | – |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $13.9M | 5.15% | 275,000 -19,500 | -7% | -$988K |
|
5
Evolent Health
EVH
$1.12B
| $13.2M | 4.88% | 520,000 | – | – |
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| $13.1M | 4.85% | 255,000 +17,500 | +7% | +$900K |
|
|
7
Sangamo Therapeutics
SGMO
$157M
| $12.3M | 4.56% | 1,400,000 +550,000 | +65% | +$4.84M |
|
|
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.2M | 4.5% | 130,000 +107,000 | +465% | +$10M |
|
|
ONCE
9
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $10.2M | 3.76% | 170,000 +35,000 | +26% | +$2.09M |
|
|
KITE
10
DELISTED
Kite Pharma, Inc.
KITE
| $9.33M | 3.45% | 90,000 +47,500 | +112% | +$4.92M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.38M | 3.1% | 105,000 +50,000 | +91% | +$3.99M |
|
|
GNMK
12
DELISTED
GenMark Diagnostics, Inc
GNMK
| $8.1M | 3% | 685,000 +285,000 | +71% | +$3.37M |
|
|
EPZM
13
DELISTED
Epizyme, Inc
EPZM
| $7.85M | 2.9% | 520,000 +35,000 | +7% | +$529K |
|
|
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
| $7.65M | 2.83% | 400,000 +140,000 | +54% | +$2.68M |
|
|
BLUE
15
DELISTED
bluebird bio
BLUE
| $6.83M | 2.53% | 65,000 +39,500 | +155% | +$4.15M |
|
|
TSRO
16
DELISTED
TESARO, Inc.
TSRO
| $6.71M | 2.48% | 48,000 +30,500 | +174% | +$4.27M |
|
17
Voyager Therapeutics
VYGR
$186M
| $6.63M | 2.45% | 740,000 +240,000 | +48% | +$2.15M |
|
18
Codexis
CDXS
$246M
| $6.49M | 2.4% | 1,190,000 +515,000 | +76% | +$2.81M |
|
|
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $5.88M | 2.17% | 215,000 +113,500 | +112% | +$3.1M |
|
|
20
Illumina
ILMN
$15.8B
| $5.47M | 2.02% | +31,500 | New | +$5.47M |
|
|
21
Gilead Sciences
GILD
$140B
| $5.31M | 1.96% | +75,000 | New | +$5.31M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $5.18M | 1.91% | 395,000 +130,000 | +49% | +$1.7M |
|
|
SYRS
23
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.93M | 1.08% | 182,141 | – | – |
|
24
CytomX Therapeutics
CTMX
$336M
| $2.75M | 1.02% | 177,500 | – | – |
|
25
Ovid Therapeutics
OVID
$91M
| $2.33M | 0.86% | +221,700 | New | +$2.33M |
|